Free Newsletter
FDA picks up the pace with warning letters
No, it's not your paranoid imagination: The FDA really has been cracking down hard on infractions of various kinds. According to BNet Pharma, FDA has issued 186 warning letters so far this year, putting it on track for another big year in enforcement. And there are some movements afoot that could make the agency even more vigilant.
In 2009, FDA dispatched 570 warning letters, more than it had sent in many years. By contrast, it sent out only 436 in 2008 and 381 in 2007. These stats include letters about misleading advertising and missives warning of manufacturing deficiencies.
It's not as if FDA Commissioner Margaret Hamburg (photo) didn't warn us; she issued something of a manifesto on stepped-up enforcement last year. But government types have been known to vow changes and then fail to follow through. Apparently, that's not happening on Hamburg's watch.
And there's more ahead. Consider the "Bad Ad" program Hamburg unveiled earlier this week. By asking doctors to tattle on misleading promos and other marketing infractions, the agency isn't just looking for more enforcement tips, but to deter bad actors from the get-go, some industry observers say.
- get the BNet post
- see a Q&A at Pharmalot
Related Articles:
FDA launches Bad Ad Program
FDA chastises Roche, Sanofi for drug promos
FDA acts faster on drug-ad missteps
Call Big Pharma a DTC conservative
Changes for a faster, more aggressive FDA
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: